deCODE is a bio-pharmaceutical company developing products to improve the treatment, diagnosis and prevention of common diseases. The company applies its capabilities in chemistry and structural biology to the development of drugs and its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases.

deCODE has therapeutic programs for the prevention of arterial thrombosis, for the prevention of heart attack, and to combat memory loss and cognitive deficits associated with Alzheimer’s and other disorders.

Through its CLIA-registered laboratory, deCODE offers a growing range of tests to assess individual risk and empower the prevention of type 2 diabetes, atrial fibrillation and stroke, heart attack, prostate cancer, glaucoma, and the common forms of breast cancer. The company also offers deCODEme™, the first personal genome scan to enable individuals to get a detailed and scientifically validated look at their own genome and what it can tell them about their susceptibility to a range of common diseases and other traits.